Investment
Features
FeesSafety
Academy
More
Pluang+

Stellantis Q3 sales steady; 2026 YTD sales up 3% with strong Ram and Jeep growth

Company Fundamentals
01 Oct 2026
PRNewsWire
View Source
Bullish
Stellantis Q3 sales steady; 2026 YTD sales up 3% with strong Ram and Jeep growth

Stellantis reported steady vehicle sales in Q3 2026 with 324,277 units sold, maintaining levels from Q3 2025. Year-to-date sales rose 3% compared to the same period last year, driven by strong performances from Ram, Jeep, Chrysler, and Dodge brands. Notably, Ram 1500 sales surged 73%, and Jeep's Cherokee Hybrid retail sales jumped 53% from Q2 to Q3 2026. The company plans to focus on disciplined execution and sustainable growth in Q4, with new model launches like the 2027 Ram 1500 Rumble Bee and Alfa Romeo's 2027 Giulia and Stelvio buzz models expected soon.

Stellantis' Q3 2026 sales performance is presented here alongside Pluang's Consumer Cyclical sector market data. Of 112 priced US stocks in this sector on Pluang, 45 rose and 66 fell today. Notable movers include Las Vegas Sands Corp. at USD 36.72 with a -2.88% change, Plby Group Inc at USD 1.00 with a -2.72% change, and Wynn Resorts, Limited at USD 77.27 with a -2.72% change, as of Oct 01, 2026 23:02 WIB.

More News

Foghorn Therapeutics cuts price target after ending Lilly partnership and cutting 40% workforce

Foghorn Therapeutics cuts price target after ending Lilly partnership and cutting 40% workforce

Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...

Market News
Bearish
44 minutes ago
RPM International Q3 2026 earnings expected to show growth with EPS of $1.95 and $2.22B revenue.

RPM International Q3 2026 earnings expected to show growth with EPS of $1.95 and $2.22B revenue.

RPM International is set to report its Q3 2026 earnings on October 6, with analysts forecasting earnings per share of $1.95 and revenue of $2.22 billion, both higher than the previous year. Despite a slight recent dip in the EPS estimate, the report ...

Company Fundamentals
Neutral
57 minutes ago
Jefferies raises Regeneron price target to $930 on new $1B Sanofi partnership for antibody drugs

Jefferies raises Regeneron price target to $930 on new $1B Sanofi partnership for antibody drugs

Jefferies increased its price target for Regeneron to $930, citing an expanded partnership with Sanofi to develop four new long-acting antibodies targeting inflammatory pathways. Sanofi will pay Regeneron $1 billion upfront, with potential milestone ...

Analyst Insights
Bullish
1 hour ago
McCormick beats Q3 estimates with 17.4% sales growth despite volume decline

McCormick beats Q3 estimates with 17.4% sales growth despite volume decline

McCormick & Company reported fiscal Q3 results with adjusted EPS of $0.86, surpassing estimates of $0.76, and revenue of $2.02 billion, up 17.4% from last year. Growth was driven by the McCormick de Mexico acquisition, pricing actions, and favorable ...

Company Fundamentals
Bullish
1 hour ago
Aehr Test Systems expects strong Q3 earnings and 160-200% revenue growth in fiscal 2027 driven by AI chip demand.

Aehr Test Systems expects strong Q3 earnings and 160-200% revenue growth in fiscal 2027 driven by AI chip demand.

Aehr Test Systems is set to report Q3 earnings of $0.11 per share and revenue around $27 million, marking a 1,000% increase in earnings year-over-year. The company projects fiscal 2027 revenue growth between 160% and 200%, reaching $130-$150 million,...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App